drugset / Trial / NCT00826358

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

NCT00826358

Phase 1 Completed 90 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Timeline

Start
2008-11
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-143 Unknown 5 mg
Subject ABT-143 Unknown 45 mg
Comparator ABT-335 Small molecule 45 mg
Comparator Rosuvastatin Small molecule 5 mg

Indications

No indication recorded.